US demand to grow 5.5% annually through 2014 Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a variety of new vaccines for travel and biodefense. New routine vaccines to boost adult, adolescent segment Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters against tetanus, diphtheria, pertussis and other diseases. Combination vaccines to pace pediatric products Among vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines. This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for Rotavirus, continue to mature and to reach greater immunization coverage. Many new therapeutic vaccines showing promise Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV, HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline, including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague. Study coverage This new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and minor product group. The study also considers market environment factors, details industry structure, evaluates company market share and profiles 17 industry participants.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
US Vaccines Market
Published on September 2010
Report Summary
US demand to grow 5.5% annually through 2014
Demand for vaccines is forecast to increase 5.5 percent annually to more than $14 billion in 2014. The market has experienced
dramatic growth due to increasing routine seasonal influenza immunization and the rising number of preventive and booster vaccines
available for adults and adolescents. This growth will be compounded as several new therapeutic vaccines for cancer reach the
market, followed in the coming years by biological treatments for Respiratory Syncytial Virus (RSV) and Alzheimer's Disease, and a
variety of new vaccines for travel and biodefense.
New routine vaccines to boost adult, adolescent segment
Pediatric vaccines have been the mainstay of the vaccine market for many years, growing steadily as new products emerged and as
a greater number of routine vaccinations were encouraged. Now, a substantial number of primary vaccines and boosters are being
recommended for adolescents and older adults, and the market for vaccines has expanded dramatically with the addition of these
populations to the target markets for vaccine producers. Significant growth in the market has been fueled by the introduction of a
vaccine for Human Papillomavirus (HPV), recommended for girls and young women and now being considered for males and a wider
age range. Seasonal influenza vaccination is also gaining ground and represents a substantial portion of growth in adult vaccines, as
new preventive treatments against zoster and meningococcal disease. Also a factor in adult vaccines is the growing use of boosters
against tetanus, diphtheria, pertussis and other diseases.
Combination vaccines to pace pediatric products
Among vaccines for children, sales will be affected by the expiration of patent protection for many of the most widely used vaccines.
This has encouraged producers to develop several new combination vaccines, which will serve to maintain the value of products while
decreasing the burden of multiple individual injections. Traditional DTaP (diphtheria, tetanus, pertussis) vaccines are being
supplemented by products for Hepatitis B and polio or Haemophilus b. Also being developed are vaccines to address a wider range of
bacterial serotypes, as with Wyeth's blockbuster PREVNAR7, which has been expanded to address 13 serotypes and which is
recommended as a supplement for children who already received the earlier vaccine. Relatively new vaccines, such as that for
Rotavirus, continue to mature and to reach greater immunization coverage.
Many new therapeutic vaccines showing promise
Vaccine demand will be spurred considerably by a number of therapeutic vaccines for cancer that are nearing completion of clinical
trials and are poised for FDA approval. There are currently 50 cancer vaccines in phase III or later trials, and the activity surrounding
cancer vaccine development is expected to continue at a high pace. Also showing promise are vaccines being developed for RSV,
HIV and Alzheimer's Disease. Similarly, a range of vaccines for travel, developing countries and biodefense are in the pipeline,
including prophylactics for malaria, hemorrhagic fevers, West Nile virus and plague.
Study coverage
This new industry study presents historical demand data (1999, 2004 and 2009) plus forecasts for 2014 and 2019 by major and
US Vaccines Market (From Slideshare) Page 1/4

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
minor product group. The study also considers market environment factors, details industry structure, evaluates company market
share and profiles 17 industry participants.
US Vaccines Market (From Slideshare) Page 2/4

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
US Vaccines Market
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 4 700.00 Quantity: _____
Corporate License--USD 7 300.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
US Vaccines Market (From Slideshare) Page 3/4

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
US Vaccines Market (From Slideshare) Page 4/4